EcoDrugPlus

Neurotrophic Tyrosine Kinase, Receptor, Type 1

Ensembl ID : ENSEEEG00000020058
Gene Symbol: NTRK1
4 Cross references
200 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 2b

Ensembl ID : ENSEEEG00000015008
Gene Symbol: NTRK2B
1 Cross references
213 Possible Orthologues:

Neurotrophic Tyrosine Kinase, Receptor, Type 3a

Ensembl ID : ENSEEEG00000018484
Gene Symbol: NTRK3A
2 Cross references
157 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2a

Ensembl ID : ENSEEEG00000010397
Gene Symbol: NFE2L2A
4 Cross references
216 Possible Orthologues:

Nicastrin

Ensembl ID : ENSEEEG00000016695
Gene Symbol: NCSTN
4 Cross references
204 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSEEEG00000019966
Gene Symbol: NAMPT
4 Cross references
219 Possible Orthologues:

Nischarin

Ensembl ID : ENSEEEG00000008053
Gene Symbol: NISCH
4 Cross references
210 Possible Orthologues:

Nitric Oxide Synthase 2

Ensembl ID : ENSEEEG00000020232
Gene Symbol: NOS2
2 Cross references
167 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSEEEG00000022280
Gene Symbol: NOTCH1B
4 Cross references
199 Possible Orthologues:

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSEEEG00000019023
Gene Symbol: NFKB1
4 Cross references
202 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 3

Ensembl ID : ENSEEEG00000020215
Gene Symbol: NR1H3
4 Cross references
392 Possible Orthologues:

Nuclear Receptor Subfamily 1, Group H, Member 4

Ensembl ID : ENSEEEG00000006931
Gene Symbol: NR1H4
4 Cross references
388 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).